Cargando…

Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis, and its role in cancer biology has been widely studied. Many cancer therapies target angiogenesis, with a focus being on VEGF-mediated signaling such as antibodies to VEGF. However, it is difficult to predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Finley, Stacey D, Engel-Stefanini, Marianne O, Imoukhuede, PI, Popel, Aleksander S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229549/ https://www.ncbi.nlm.nih.gov/pubmed/22104283 http://dx.doi.org/10.1186/1752-0509-5-193

Ejemplares similares

A Two-Compartment Model of VEGF Distribution in the Mouse
por: Yen, Phillip, et al.
Publicado: (2011)

Expression of VEGF Receptors on Endothelial Cells in Mouse Skeletal Muscle
por: Imoukhuede, Princess I., et al.
Publicado: (2012)

Compartment Model Predicts VEGF Secretion and Investigates the Effects of VEGF Trap in Tumor-Bearing Mice
por: Finley, Stacey D., et al.
Publicado: (2013)

The Presence of VEGF Receptors on the Luminal Surface of Endothelial Cells Affects VEGF Distribution and VEGF Signaling
por: Stefanini, Marianne O., et al.
Publicado: (2009)

A Compartment Model of VEGF Distribution in Humans in the Presence of Soluble VEGF Receptor-1 Acting as a Ligand Trap
por: Wu, Florence T. H., et al.
Publicado: (2009)

A compartment model of VEGF distribution in blood, healthy and diseased tissues
por: Stefanini, Marianne O, et al.
Publicado: (2008)

Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model
por: Finley, SD, et al.
Publicado: (2015)

Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts
por: Imoukhuede, Princess I, et al.
Publicado: (2014)

A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF(165b) in peripheral arterial disease in human and mouse
por: Chu, Liang-Hui, et al.
Publicado: (2016)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

Targeting Neuropilin-1 to Inhibit VEGF Signaling in Cancer: Comparison of Therapeutic Approaches
por: Gabhann, Feilim Mac, et al.
Publicado: (2006)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
por: Veritti, Daniele, et al.
Publicado: (2023)

Computational Model of MicroRNA Control of HIF-VEGF Pathway: Insights into the Pathophysiology of Ischemic Vascular Disease and Cancer
por: Zhao, Chen, et al.
Publicado: (2015)

Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis
por: Vempati, Prakash, et al.
Publicado: (2011)

Quantifying the Proteolytic Release of Extracellular Matrix-Sequestered VEGF with a Computational Model
por: Vempati, Prakash, et al.
Publicado: (2010)

Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
por: Leipold, Douglas, et al.
Publicado: (2018)

A systems biology view of blood vessel growth and remodelling
por: Logsdon, Elizabeth A, et al.
Publicado: (2014)

Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial
por: Fidler, Matthew, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats
por: Bergh, Marianne Skov-Skov, et al.
Publicado: (2021)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG(2) Monoclonal Antibody, in Healthy Volunteers
por: Mathur, Mohit, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

The Angiogenic Secretome in VEGF overexpressing Breast Cancer Xenografts
por: Dore-Savard, Louis, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular Dystrophy
por: Singh, P, et al.
Publicado: (2016)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022)

A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults
por: Orito, Yuji, et al.
Publicado: (2022)

Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling
por: Wu, Qianhui, et al.
Publicado: (2020)

A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril
por: Eberlin, Marion, et al.
Publicado: (2012)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Analysis of VEGF-A Regulated Gene Expression in Endothelial Cells to Identify Genes Linked to Angiogenesis
por: Rivera, Corban G., et al.
Publicado: (2011)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
por: Elhence, Hirsh, et al.
Publicado: (2022)

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
por: Kut, C, et al.
Publicado: (2007)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
por: Wang-Lin, Shun Xin, et al.
Publicado: (2018)

Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
por: Tang, Yu, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fig16kj0l2ufuc5kbka71f471m